Is CING or SPRO more profitable?

SPRO runs the higher net margin — CING at 0.00% versus SPRO at 17.18%.

Cingulate Inc. (CING) vs Spero Therapeutics, Inc. (SPRO)

A side-by-side comparison of Cingulate Inc. and Spero Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CING

Cingulate Inc.

$67M

$4.95HealthcareDelayed quote: Oct 6, 2026, 2:13 PM EDT

SPRO

Spero Therapeutics, Inc.

$69M

$1.19HealthcareDelayed quote: Oct 6, 2026, 2:10 PM EDT

Total return — CING vs SPRO

growth of $100 · dividends reinvested · last 5y

CING -99.6% (-66.1%/yr)SPRO -91.5% (-38.9%/yr)SPRO compounded faster over this window

Log scale — wide-divergence pair

CING SPRO

CING vs SPRO: by the numbers

•SPRO is the larger company ($69M vs $67M market cap).
•SPRO is profitable (17.18% net margin) while CING runs a net loss (0.00%).

Metrics side by side

Valuation

Metric	CING	SPRO
P/E ratio	N/A	10.77
P/S ratio	N/A	1.60
P/B ratio	2.84	1.55
EV / EBITDA	0.23	3.30
FCF yield	N/A	28.54%

Profitability

Metric	CING	SPRO
Gross margin	0.00%	100.00%
Operating margin	0.00%	-0.04%
Net margin	0.00%	17.18%
ROE	-122.71%	16.70%
ROIC	-83.74%	13.12%

Growth (annualized)

Metric	CING	SPRO
Revenue CAGR (5Y)	N/A	22.93%
Total return CAGR (5Y)	N/A	-42.70%

Frequently asked

Is CING or SPRO more profitable?: SPRO runs the higher net margin — CING at 0.00% versus SPRO at 17.18%.

Go deeper

Full CING analysis Full SPRO analysis Interactive comparison tool

Dig into the metrics

Spero Therapeutics P/E ratio Cingulate ROE Spero Therapeutics ROE Cingulate operating margin Spero Therapeutics operating margin Cingulate revenue growth Spero Therapeutics revenue growth Cingulate free cash flow Spero Therapeutics free cash flow

Cingulate & Spero Therapeutics appear in these rankings

Fastest Revenue Growth Stocks Highest FCF Yield Stocks Lowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.